Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000929 · ClinicalTrials.gov registry record · Phase 1
A Study of the Effects of Advantage 24 on the Rectum
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT00000929 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 70 participants.
The verdict
NCT00000929, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is safe and acceptable for homosexual male couples, where both partners have the same HIV status, to use Advantage 24 during anal intercourse. Advantage 24 is a spermicide (a chemical that kills sperm). Much research and development is being done with chemicals that can be controlled by the receptive partner to prevent the spread of HIV and other sexually transmitted diseases (STDs). Advantage 24 currently is used in the vagina as a form of birth control. The safety of Advantage 24 is particularly important for HIV-positive men because they have a greater chance of serious reaction to Advantage 24 due to other HIV-related conditions.
Interventions
- DRUG Nonoxynol-9
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Est. Completion | 1999-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000929
The ClinicalTrials.gov registry entry for NCT00000929 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nonoxynol-9 is the first listed.
NCT00000929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000929 about?
NCT00000929 is a clinical study titled "A Study of the Effects of Advantage 24 on the Rectum". The purpose of this study is to see if it is safe and acceptable for homosexual male couples, where both partners have the same HIV status, to use Advantage 24 during anal intercourse. Advantage 24 is a spermicide (a chemical that kills sperm). Much research and development is being done with chemi...
What is the current status of trial NCT00000929?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. Estimated completion is 1999-07.
What interventions are being tested in trial NCT00000929?
The interventions under investigation include: Nonoxynol-9 (DRUG).
Who is sponsoring clinical trial NCT00000929?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.